当前位置： SCI文献检索 > LEUKEMIA RESEARCH期刊下所有文献 > Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases.

Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases.

Abstract：

:In 141 adult patients with diagnosis of acute myeloid leukemia the overall expression and intensity of expression of CD34 antigen on leukemic cells was investigated. Myeloid blasts were tested by applying direct immunofluorescence staining using anti-CD34 fluorescein monoclonal antibody in flow cytometry. CD34 antigen was found in 73 out of 141 (51%) cases and in particular in M0, M1 and M4 French-American-British (FAB) cytotypes, while M3 and M5 cases were rarely positive. In patients whose blasts expressed CD34 antigen a significantly lower rate of complete remission (CR) was observed as opposed to CD34 negative cases (61% vs 88%) (P = 0.001). Furthermore, a negative correlation between high intensity of CD34 expression, measured as a mean fluorescence index (MFI), and CR rate was observed. In particular, patients with a higher CD34 fluorescence intensity (MFI > 23), showed a further reduction in CR rate (48%). Also, these patients had a significantly lower overall survival (P = 0.03) as compared to patients with no expression of CD34 and patients with CD34 MFI < 23. In conclusion, these findings confirm that CD34 expression is frequently associated with "immature" FAB cytotypes (M0, M1 and M4) and with a reduced probability to achieve CR. Furthermore, a high CD34 intensity of expression should be considered as a reliable poor prognostic factor.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Raspadori D,Lauria F,Ventura MA,Rondelli D,Visani G,de Vivo A,Tura S

doi

10.1016/s0145-2126(97)00015-5

subject

Has Abstract

pub_date

1997-07-01 00:00:00

pages

603-7

issue

7

eissn

0145-2126

issn

1873-5835

pii

S0145212697000155

journal_volume

21

pub_type

杂志文章

相关文献

LEUKEMIA RESEARCH文献大全
  • Preclinical studies of a panel of 12 monoclonal antibodies in view of bone marrow purging in acute lymphoblastic leukemia.

    abstract：:We analysed the optimal conditions for autologous bone marrow purging using complement binding monoclonal antibodies (mAbs). Twelve mAbs belonging to four clusters (CD9, CD10, CD19, CD24), alone or combined were evaluated by using direct cytotoxicity and clonogenic assays. We observed the following data: (1) optimal c...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(87)90117-2

    authors： Racadot E,Herve P,Lamy B,Peters A

    更新日期：1987-01-01 00:00:00

  • Transcriptional profiling and assessment of cell lines as in vitro models for mantle cell lymphoma.

    abstract：:Mantle cell lymphoma (MCL) is an aggressive malignancy and new treatment modalities must be established to increase patient survival time. In the search for new therapeutic targets, reliable and well-characterised in vitro models are essential. In this study, we have characterised three MCL cell lines (SP53, Granta 51...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2004.06.009

    authors： Ek S,Ortega E,Borrebaeck CA

    更新日期：2005-02-01 00:00:00

  • SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor.

    abstract：:Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. Although several clinical characteristics can be associated with worse prognosis, more robust biological markers still remains uncovered. SMYD2, a member of SMYD protein family, regulates the activity of several proteins through methylation. I...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2014.01.013

    authors： Sakamoto LH,Andrade RV,Felipe MS,Motoyama AB,Pittella Silva F

    更新日期：2014-04-01 00:00:00

  • Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study.

    abstract：:Topotecan has demonstrable activity in high-risk MDS and CMMoL. However, the significant toxicity of topotecan administered at a dose of 2mg/m2 i.v. daily for 5 days as a continuous infusion limits its use in older patients. Therefore, we studied topotecan 1.5mg/m2 per day i.v. over 2 h for three consecutive days in 2...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/s0145-2126(03)00181-4

    authors： Vaena DA,Walker P,Pennington K,Stephens A,Stender MJ,Yiannoutsos CT,Young C,Stoner C,Cripe LD,Hoosier Oncology Group.

    更新日期：2004-01-01 00:00:00

  • Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence.

    abstract：:A single somatic mutation, V617F, in the pseudokinase domain of the Jak2 is the primary cause of many chronic myeloproliferative diseases. As valine 617 of Jak2 is conserved as valine 678 of Tyk2, we examined the effect of a homologous mutation in Tyk2 (V678F Tyk2) on cell growth. V678F Tyk2 augmented the transcriptio...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2006.08.018

    authors： Shide K,Shimoda K,Kamezaki K,Kakumitsu H,Kumano T,Numata A,Ishikawa F,Takenaka K,Yamamoto K,Matsuda T,Harada M

    更新日期：2007-08-01 00:00:00

  • Induction of differentiation of myelogenous leukemia cells by humulone, a bitter in the hop.

    abstract：:The active form of vitamin D, 1alpha,25-dihydroxyvitamin D3 (VD3), inhibits proliferation and induces differentiation of myelomonocytic leukemia cells, but its clinical use is limited by the adverse effect of hypercalcemia. VD3 mobilizes calcium stores from bone by inducing the dissolution of bone mineral and matrix. ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(98)00046-0

    authors： Honma Y,Tobe H,Makishima M,Yokoyama A,Okabe-Kado J

    更新日期：1998-07-01 00:00:00

  • The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.

    abstract：:Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor (G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated wi...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.02.002

    authors： Salar A,Haioun C,Rossi FG,Duehrsen U,Pettengell R,Johnsen HE,Jaeger U,Verhoef G,Schwenkglenks M,Bacon P,Bendall K,Lugtenburg PJ

    更新日期：2012-05-01 00:00:00

  • The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells.

    abstract：:AML progenitor cells (AML-PC) undergo significant apoptosis in response to the deacetylase inhibitor (DACi) LAQ824 and lose the replating capacity which was not observed with the DACi valproic acid. Treatment of normal hematopoietic progenitor cells (HPC) with LAQ824 resulted in (i) inhibition of differentiation, (ii)...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2010.06.024

    authors： Schwarz K,Romanski A,Puccetti E,Wietbrauk S,Vogel A,Keller M,Scott JW,Serve H,Bug G

    更新日期：2011-01-01 00:00:00

  • Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.

    abstract：:Forty patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) preceded by MDS were treated with intensive induction and consolidation chemotherapy in a prospective multicenter pilot study. They were given two cycles of cytarabine 100 mg/m with 12-h intervals on days 1-7 and idarubicin 12...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/s0145-2126(96)00116-6

    authors： Ruutu T,Hänninen A,Järventie G,Koistinen P,Koivunen E,Kätkä K,Nousiainen T,Oksanen K,Pelliniemi TT,Remes K,Timonen T,Volin L,Elonen E

    更新日期：1997-02-01 00:00:00

  • Non-Hodgkin's lymphoma: case control epidemiological study in Yorkshire.

    abstract：:This paper reports the results of a case control study of non-Hodgkin's lymphoma in the Yorkshire Health Region. In all, 437 cases and 724 controls were interviewed. Risk factors associated with past skin conditions, family history of cancer and infectious mononucleosis, aspects of social life and contact with wood du...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(98)80012-x

    authors： Cartwright RA,McKinney PA,O'Brien C,Richards ID,Roberts B,Lauder I,Darwin CM,Bernard SM,Bird CC

    更新日期：1988-01-01 00:00:00

  • Reversing the multidrug resistance in acute leukemia: until the leukemia initiating cell?

    abstract：:Reversal of drug resistance is of pivotal importance in order to improve the results of chemotherapy. Monitoring of such reversal is necessary in order to analyze the results of clinical trials. Nonetheless, the leukemia cell population to eradicate is the leukemia initiating cells characterized by a CD34+CD38- phenot...

    journal_title：Leukemia research

    pub_type： 评论,社论

    doi：10.1016/j.leukres.2008.09.022

    authors： Costello RT

    更新日期：2009-06-01 00:00:00

  • Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific.

    abstract：:Internal tandem duplications (ITDs) of the FLT3 gene occur in approximately 20-30% of acute myeloid leukemia (AML) patients. We investigated if FLT3 ITDs could be used as minimal residual disease (MRD) markers for AML patients. Patient-specific polymerase chain reaction (PCR) assays for FLT3 ITDs were developed for fo...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(01)00087-x

    authors： Stirewalt DL,Willman CL,Radich JP

    更新日期：2001-12-01 00:00:00

  • Dasatinib first-line: Multicentric Italian experience outside clinical trials.

    abstract：:Dasatinib was approved for the treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients in first line therapy based on the demonstration of efficacy and safety reported in patients enrolled in clinical trials. We describe a multicentric Italian "real-life" experience of dasatinib used as frontline treat...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2015.11.008

    authors： Breccia M,Stagno F,Luciano L,Abruzzese E,Annunziata M,D'Adda M,Maggi A,Sgherza N,Russo-Rossi A,Pregno P,Castagnetti F,Iurlo A,Latagliata R,Cedrone M,Di Renzo N,Sorà F,Rege-Cambrin G,La Nasa G,Scortechini AR,Greco G

    更新日期：2016-01-01 00:00:00

  • Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.

    abstract：:This retrospective study of the thrombocythemia Italian registry (RIT) documented that 71 (30.6%) out of 232 ET patients experienced 88 cardiovascular adverse events (CV-AEs) during anagrelide treatment (522 pt-y). The rate of CV-AEs was: 24.1% for palpitations, 4.3% for angina, 3.5% for arterial hypertension, 3.0% fo...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2011.06.030

    authors： Gugliotta L,Tieghi A,Tortorella G,Scalzulli PR,Ciancia R,Lunghi M,Cacciola E,Cacciola R,Candoni A,Crugnola M,Codeluppi K,Usala E,Specchia G,Martinelli V,Palmieri F,Pierri I,Liberati AM,Iurlo A,Grossi A,Vannucchi AM

    更新日期：2011-12-01 00:00:00

  • Development of a mantle cell lymphoma in an ATM heterozygous woman after occupational exposure to ionising radiation and somatic mutation of the second allele.

    abstract：:Predisposition to lymphomagenesis is a well-known phenomenon of ataxia-telangiectasia, a recessive disorder caused by germline inactivation of ATM. ATM encodes a protein implicated in the repair of radiation induced double-strand breaks. Biallelic ATM inactivation was described also in sporadic lymphoid malignancies, ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2005.11.010

    authors： Briani C,Schlotter M,Lichter P,Kalla C

    更新日期：2006-09-01 00:00:00

  • Angiogenic factors in chronic lymphocytic leukemia.

    abstract：:Angiogenesis is a complex process controlled by the balance of a large number of regulating factors, the pro- and anti-angiogenic factors. Dysregulation of angiogenesis occurs in various pathologies and is one of the hallmarks for cancer. Recent emphasis on the microenvironment's influence in chronic lymphocytic leuke...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2012.05.021

    authors： Xia Y,Lu RN,Li J

    更新日期：2012-10-01 00:00:00

  • Expression of IL-18 and its receptor in human leukemia cells.

    abstract：:The importance of IL-18, although clearly established in solid tumors, has not been fully elucidated in human hematopoietic neoplasms. Here we examined the mRNA and protein for IL-18 in eight human hematopoietic cell lines representing different lineages and neoplasms including leukemia, lymphoma and others. Our resul...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(03)00005-5

    authors： Zhang B,Ma XT,Zheng GG,Li G,Rao Q,Wu KF

    更新日期：2003-09-01 00:00:00

  • Variant cell lines from the human promyelocyte line HL60.

    abstract：:The continuous human promyeloid cell line HL60 may be induced to differentiate into neutrophils by the presence of 1.25% dimethylsulphoxide (DMSO) and related compounds [4]. When treated with 12-O-tetradecanoylphorbol-13-acetate (TPA), the cells exhibit may features characteristic of monocytes/macrophages [13]. In bot...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(82)90006-6

    authors： Toksoz D,Bunce CM,Stone PC,Michell RH,Brown G

    更新日期：1982-01-01 00:00:00

  • Susceptibility of mantle cell lymphomas to reovirus oncolysis.

    abstract：:Mantle cell lymphoma (MCL) an incurable B-cell, non-Hodgkin lymphoma (NHL) urgently requires new treatments. We assessed reovirus mediated oncolysis in a panel of human MCL cell lines. In vitro, we found the cytopathic effect of reovirus infection ranged from high to very limited and correlated with levels of Ras acti...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.05.020

    authors： Alain T,Muzik H,Otsuka S,Chan S,Magliocco T,Diaz R,Forsyth PA,Morris D,Bebb G

    更新日期：2010-01-01 00:00:00

  • Differentiation restriction in the neutrophil-granulocyte, macrophage, eosinophil-granulocyte pathway: analysis by equilibrium density centrifugation.

    abstract：:Bone marrow culture techniques and equilibrium density centrifugation of human bone marrow cells were used to analyse the neutrophil-granulocyte, macrophage and eosinophil-granulocyte progenitor hierarchy. The buoyant density of progenitor cells changes as cells differentiate down the granulocyte-macrophage pathway an...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(82)90061-3

    authors： Guimaraes JE,Francis GE,Bol SJ,Berney JJ,Hoffbrand AV

    更新日期：1982-01-01 00:00:00

  • Changes in the surface marker pattern related to maturation in adult acute myeloid leukaemia.

    abstract：:Introduction of the maturation index (MI) as a measure for the degree of maturation improved the subtyping of acute myeloid leukemia (AML). A comparison is made here between the MI and the results of surface marker analysis with a panel of monoclonal antibodies (McAb) in the immunofluorescence technique. The McAb appl...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(83)90100-5

    authors： van Rhenen DJ,van der Reijden HJ,van't Veer MB,Engelfriet CP,von dem Borne AE,Langenhuijsen MM

    更新日期：1983-01-01 00:00:00

  • Pyothorax-associated lymphoma (PAL) with biclonal Epstein-Barr virus infection: characterization of a novel PAL cell line with unique features.

    abstract：:Pyothorax-associated lymphoma (PAL) is a representative form of diffuse large B-cell lymphoma associated with chronic inflammation, in which the Epstein-Barr virus (EBV) genome is consistently detectable in the lymphoma cells of all PAL cases. Cell lines and animal models would be useful for understanding better this ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2013.07.033

    authors： Taniguchi A,Hashida Y,Nemoto Y,Taguchi T,Iwahara Y,Daibata M

    更新日期：2013-11-01 00:00:00

  • 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.

    abstract：:3q26.2/EVI1 rearrangements resulting in EVI1 overexpression play an important role in leukemogenesis and are associated with treatment resistance and a poorer prognosis in patients with acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia and BCR-ABL negative myeloproliferative neoplasms. In this...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2017.12.004

    authors： Hu Z,Hu S,Ji C,Tang Z,Thakral B,Loghavi S,Medeiros LJ,Wang W

    更新日期：2018-02-01 00:00:00

  • Phenotypic and functional characterization of mobilized peripheral blood CD34+ cells coexpressing different levels of c-Kit.

    abstract：:In this report we evaluated the exact expression pattern of c-Kit on mobilized peripheral blood (PB) CD34+ cells. Using a monoclonal antibody against CD117 antigen (95C3), flow cytometric analysis revealed that approximately 25% of the mobilized PB CD34+ cells coexpress c-Kit. This cell fraction showed a considerable ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(98)00002-2

    authors： Kuçi S,Taylor G,Neu S,Schumm M,Niethammer D,Handgretinger R

    更新日期：1998-04-01 00:00:00

  • Continuous intravenous infusion of high dose recombinant interleukin 2 for advanced lymphomas--a phase II study.

    abstract：:The prognosis of patients with advanced refractory lymphoma remains poor. We have carried out a Phase II study of continuous high dose intravenous recombinant interleukin 2 alone without LAK cells in this group of patients. Eight patients have so far been treated, 4 with non-Hodgkins lymphoma and 4 with Hodgkins disea...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/0145-2126(91)90053-v

    authors： Lim SH,Worman CP,Callaghan T,Jewell A,Smith MP,Goldstone AH

    更新日期：1991-01-01 00:00:00

  • A cytogenetic model predicts relapse risk and survival in patients with acute myeloid leukemia undergoing hematopoietic stem cell transplantation in morphologic complete remission.

    abstract：:Up to 30% of patients with acute myeloid leukemia (AML) and abnormal cytogenetics have persistent cytogenetic abnormalities (pCytAbnl) at morphologic complete remission (mCR). We hypothesized that the prognostic significance of pCytAbnl in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) i...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.leukres.2014.11.007

    authors： Rashidi A,Cashen AF

    更新日期：2015-01-01 00:00:00

  • In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.

    abstract：:Leukemic cells from 85 children with newly diagnosed precursor B-lineage ALL were tested for in vitro drug sensitivity to a panel of anti-cancer drugs. Minimal residual disease (MRD) was measured by RQ-PCR. There was a significant correlation between MRD day 29 and in vitro sensitivity to prednisolone (p<0.001) and do...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.06.012

    authors： Lönnerholm G,Thörn I,Sundström C,Frost BM,Abrahamsson J,Behrendtz M,Heldrup J,Jacobsson S,Li A,Olofsson T,Porwit A,Söderhäll S,Larsson R,Forestier E

    更新日期：2009-01-01 00:00:00

  • Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.

    abstract：OBJECTIVE:Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (MM) with an overall response rate of 92% and a CR rate of 18% (Alexanian et al, Hematology 2007;12(3):235-9), but this regimen has not been tested in the Chinese patients. We report here our results tes...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.04.006

    authors： Zheng W,Wei G,Ye X,He J,Li L,Wu W,Shi J,Zhang J,Huang W,Xie W,Luo Y,Xue X,Lin M,Huang H,Cai Z

    更新日期：2009-12-01 00:00:00

  • Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy.

    abstract：:Outcomes in patients with secondary acute myeloid leukemia (sAML) (including therapy related myeloid neoplasms and AML with myelodysplasia related changes (MRC)) are poor. Patients treated with hypomethylating agents (HMAs) for antecedent hematological malignancy (AHM) have suboptimal responses to induction chemothera...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2020.106367

    authors： Talati C,Goldberg AD,Przespolewski A,Chan O,Ali NA,Kim J,Famulare C,Sallman D,Padron E,Kuykendall A,Lancet JE,Wang E,Tallman MS,Komrokji R,Sweet K

    更新日期：2020-06-01 00:00:00

  • MTHFR 677CC/1298CC genotypes are highly associated with chronic myelogenous leukemia: a case-control study in Korea.

    abstract：:Methylenetetrahydrofolate reductase (MTHFR) is an enzyme involved in folate metabolism and DNA methylation. Studies on MTHFR polymorphism in leukemia have largely focused on the protective role of MTHFR polymorphism in acute lymphoblastic leukemia (ALL). We evaluated the C677T and A1298C polymorphisms using the TaqMan...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2006.10.016

    authors： Moon HW,Kim TY,Oh BR,Min HC,Cho HI,Bang SM,Lee JH,Yoon SS,Lee DS

    更新日期：2007-09-01 00:00:00